Quality of Life and Nutritional Improvements in Cirrhotic Patients
Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33606
- Tampa General Medical Group
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female gender of Age 18 years or older
- Liver cirrhosis defined as one or more of the following: Radio-graphically proven portal hypertension (CT with nodular appearance) or Liver biopsy with cirrhosis
- Model for End Stage Liver Disease (MELD) score < 20
- Willingness to provide written informed consent, and participate in all study requirements
- Sodium greater than 130 meq/L
- Conn Score < 2
Exclusion Criteria:
- Active alcohol consumption
- Serum total bilirubin level > 5 mg/dl
- History of hepatocellular carcinoma (HCC) and malignancies other than basal cell carcinoma of the skin
- Pregnant or breastfeeding women
- Subject has renal insufficiency requiring routine dialysis
- Poorly controlled diabetes as defined by HgA1C > 10
- Narcotic/psychotropic usage other than a stable dose of antidepressant and/or methadone. Neurontin (gabapentin) and Lyrica (pregabalin) are permitted if the subject has been on a stable dose for at least 2 months prior to the screening visit and no change of dosing is expected throughout the length of the trial
- Any of the following diagnoses:
- HIV
- Evidence of severe concomitant illness or any condition that makes them unsuitable for the study in the opinion of the investigator(s)
- Subject has received an investigational drug within 30 days prior to enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Lactulose and Rifaximin Placebo
Standard portal hypertension care, standard nutritional advice, Lactulose 30ml three times a day and Rifaximin (Xifaxan) Placebo twice a day.
|
Lactulose 30ml by mouth three times a day
Other Names:
Rifaximin Placebo twice a day
Other Names:
|
|
ACTIVE_COMPARATOR: Rifaximin and Lactulose Placebo
Rifaximin (Xifaxan) twice a day and Lactulose Placebo three times a day.
|
Rifaximin 550mg by mouth twice a day
Other Names:
Lactulose Placebo 30ml three times a day
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Outcomes of Change in Quality of Life Assessment Between the Two Groups
Time Frame: Participants will be followed for 180 days
|
Quality of Life will be determined by the Chronic Liver Disease Foundation Questionnaire (CLDQ), the Sleep Scale by Hays, R.D.&Stewart, A.L. and the Multidimensional Assessment of Fatigue (MAF) Scale and measured based upon Subjective Global Assessment (SGA).
|
Participants will be followed for 180 days
|
|
Nutritional Improvement Between the Two Groups
Time Frame: Participants will be followed for 180 days
|
These outcomes will be determined as Body Composition Analysis via the Quadscan 4000 BIA device manufactured by Bodystat;calories burned, steps taken and levels of physical activity to sleep efficiency will be measured via the Bodymedia CORE Fit actigraph device and various standard of care laboratories.
|
Participants will be followed for 180 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Markers of improvement in general health
Time Frame: Participants will be followed for 180 days
|
These outcomes will be determined as Body Composition Analysis via the Quadscan 4000 BIA device manufactured by Bodystat;calories burned, steps taken and levels of physical activity to sleep efficiency will be measured via the Bodymedia CORE Fit actigraph device and various standard of care laboratories.
|
Participants will be followed for 180 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Guy Neff, MD, MBA, Tampa General Medical Group
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Liver Failure
- Hepatic Insufficiency
- Pathologic Processes
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Liver Diseases
- Fibrosis
- Brain Diseases, Metabolic
- Liver Cirrhosis
- Hepatic Encephalopathy
- Brain Diseases
- Hypertension, Portal
- Anti-Infective Agents
- Gastrointestinal Agents
- Anti-Bacterial Agents
- Rifaximin
- Lactulose
Other Study ID Numbers
Other Study ID Numbers
- Rifaximin and Nutrition
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.